Clinical trials: Nasal Polyp
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GB001 in Adult Participants With Chronic Rhinosinusitis
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients…
- Trial name
- NCT03956862
- Testing
- GB001
- Where
- 38 sites in United States, Czechia and 1 more
- Volunteers
- 97 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Nasal Polyps
Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)
This is a randomized, double blind, placebo controlled, parallel group phase III study designed to assess the clinical efficacy and safety of 100 milligrams (mg) subcutaneous (SC) mepolizumab treatment in adults with CRSwNP/ECRS…
- Trial name
- MERIT (NCT04607005)
- Testing
- Mepolizumab, Standard of care
- Where
- Japan
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Chronic Sinusitis, Nasal Polyposis
Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)
The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in chronic sinusitis (CS) patients with recurrent nasal polyps.
- Trial name
- NCT03358329
- Testing
- S8 Sinus Implant
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Intersect ENT
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis
Dupilumab in CRSsNP
Primary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: To evaluate the…
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder
- Trial name
- Liberty CRSsNP (NCT04678856)
- Testing
- Dupilumab SAR231893
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 71 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and…
- Trial name
- SINUS-52 (NCT02898454)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate nasal spray
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 448 people
- Sponsor
- Sanofi
Chronic Sinusitis, Nasal Polyps
Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps
The RESOLVE Study is a randomized controlled trial with the S8 Sinus Implant in 100 chronic sinusitis patients with recurrent nasal polyps.
- Trial name
- RESOLVE (NCT01732536)
- Testing
- S8 Sinus Implant, Mometasone furoate nasal spray
- Where
- 19 sites in United States
- Volunteers
- 100 people
- Sponsor
- Intersect ENT
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Nasal Polyps
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg, compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing endoscopic nasal polyp score in adult (≥ 18 years)…
- Trial name
- THUNDER (NCT03681093)
- Testing
- Fevipiprant 150 mg, Fevipiprant 450 mg
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
This was a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately…
- Trial name
- NCT05049122
- Testing
- Dupilumab SAR231893
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Sanofi
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Phase 2, open-label, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 6 months in subjects with chronic sinusitis with nasal polyps and eosinophilia.
- Trial name
- CS201 (NCT02217332)
- Testing
- dexpramipexole
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Knopp Biosciences
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 milligram (mg) every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity…
- Trial name
- SINUS-24 (NCT02912468)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate 50 micrograms
- Where
- 76 sites in United States, Bulgaria and 11 more
- Volunteers
- 276 people
- Sponsor
- Sanofi
Nasal Polyps
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo.
- Trial name
- NCT01920893
- Testing
- Dupilumab, Mometasone furoate nasal spray
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with…
- Trial name
- NCT03960580
- Testing
- OPN-375
- Where
- 87 sites in United States, Australia and 8 more
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.
Nasal Polyps
Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex.
- Trial name
- NCT03085797
- Testing
- Mepolizumab, Mometasone furoate
- Volunteers
- 414 people
- Sponsor
- GlaxoSmithKline
Bilateral Nasal Polyposis
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral…
- Trial name
- NCT01622569
- Testing
- Fluticasone Propionate
- Where
- 33 sites in United States, Canada
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with…
- Trial name
- NCT03781804
- Testing
- OPN-375
- Where
- 92 sites in United States, Bulgaria and 6 more
- Volunteers
- 332 people
- Sponsor
- Optinose US Inc.
Healthy, Chronic Rhinosinusitis With Nasal Polyps
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with…
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Trial name
- NCT02743871
- Testing
- PF-06817024
- Where
- 20 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nasal Polyps
12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or…
- Trial name
- NCT01623310
- Testing
- Fluticasone Propionate
- Where
- 16 sites in United States
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.